Notably, the DCUN1D1 mutation was unique to the PDX and cell line (Figure 7E), suggesting the tumor from which this PDX was derived may have harbored unique genetics that could contribute to increased bortezomib sensitivity. This evidence concerns the gene DCUN1D1 and neoplasm.